Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pignata

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 13, 2018
Trabectedin in Ovarian Cancer: is it now a Standard of Care?J Ventriglia, I Paciolla, S C Cecere, et al.
Anticancer Research|March 28, 2001
Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancerS De Placido, S Tramontana, E Ferrari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2000
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancerS Pignata, E Varriale, G Casella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancerR Tambaro, S Greggi, R V Iaffaioli, et al.
British Journal of Cancer|June 13, 2013
Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovaryG Mangili, J Ottolina, A Gadducci, et al.
Anticancer Research|August 21, 2003
Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinomaA Ottaiano, R Tambaro, S Greggi, et al.
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2012
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trialM Brundage, M Gropp, F Mefti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2016
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 studyG Mangili, C Sigismondi, D Lorusso, et al.
International Journal of Oncology|April 30, 2011
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancerS Pignata, R Lauria, F Perrone, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 13, 2018
Trabectedin in Ovarian Cancer: is it now a Standard of Care?J Ventriglia, I Paciolla, S C Cecere, et al.
Anticancer Research|March 28, 2001
Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancerS De Placido, S Tramontana, E Ferrari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2000
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancerS Pignata, E Varriale, G Casella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancerR Tambaro, S Greggi, R V Iaffaioli, et al.
British Journal of Cancer|June 13, 2013
Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovaryG Mangili, J Ottolina, A Gadducci, et al.
Anticancer Research|August 21, 2003
Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinomaA Ottaiano, R Tambaro, S Greggi, et al.
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2012
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trialM Brundage, M Gropp, F Mefti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2016
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 studyG Mangili, C Sigismondi, D Lorusso, et al.
International Journal of Oncology|April 30, 2011
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancerS Pignata, R Lauria, F Perrone, et al.
Pageof 12